Amneal Plans ‘Meaningful Additions’ To Its Generics Portfolio
As Company Sees Increase In Its Generics Sales And Overall Revenues
Executive Summary
Amneal continues to focus on new generics launches as the company sees its quarterly and half-yearly revenues increase on the back of its new launches and generics portfolio. The US-based company said that it was looking to continue its shift towards complex generics, as it considers eventually building in-house capabilities for biosimilars.
You may also be interested in...
Amneal Delivers On Biosimilars Ambitions With Neupogen Rival
Amneal has laid out its plans to enter the US biosimilars market after receiving FDA approval for its first biosimilar, a Neupogen rival known as Releuko (filgrastim-ayow) that was developed with partner Kashiv Biosciences. Amneal also intends to launch two more biosimilars soon, along with 20-30 generics launches planned in 2022.
Amneal Acquires India’s Puniska To Double Injectables Business
Amneal has acquired India’s Puniska Pharmaceticals in a deal worth $93m, with an aim to “more than double” its injectables business by 2025. Meanwhile, in the third quarter the company has reported growth in its generics and specialty segments, with Amneal looking to enter the biosimilars market next year.
Amneal Takes A Step Forward On Biosimilars
The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.